PULM Fundamental Analysis - PULMATRIX INC

Name: PULMATRIX INC (PULM) Stock
Brand: PULMATRIX INC
Rating: 4 (3 reviews)

Fundamental Rating

Taking everything into account, PULM scores 3 out of 10 in our fundamental rating. PULM was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability. PULM is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

PULM had negative earnings in the past year.

In the past year PULM has reported a negative cash flow from operations.

In the past 5 years PULM always reported negative net income.

In the past 5 years PULM always reported negative operating cash flow.

1.2 Ratios

PULM has a worse Return On Assets (-124.85%) than 81.77% of its industry peers.

Looking at the Return On Equity, with a value of -131.42%, PULM is doing worse than 65.63% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-124.85%
ROE	-131.42%
ROIC	N/A

ROA(3y)-61.24%

ROA(5y)-54.83%

ROE(3y)-81.96%

ROE(5y)-75.71%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.

PULM has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for PULM has been increased compared to 5 years ago.

There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -46.25, we must say that PULM is in the distress zone and has some risk of bankruptcy.

PULM has a Altman-Z score of -46.25. This is amonst the worse of the industry: PULM underperforms 90.63% of its industry peers.

PULM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-46.25

ROIC/WACCN/A

WACC8.84%

2.3 Liquidity

A Current Ratio of 19.97 indicates that PULM has no problem at all paying its short term obligations.

With an excellent Current ratio value of 19.97, PULM belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.

A Quick Ratio of 19.97 indicates that PULM has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 19.97, PULM belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	19.97
Quick Ratio	19.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PULM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.59%, which is quite impressive.

Looking at the last year, PULM shows a very negative growth in Revenue. The Revenue has decreased by -99.97% in the last year.

Measured over the past years, PULM shows a decrease in Revenue. The Revenue has been decreasing by -0.26% on average per year.

EPS 1Y (TTM)35.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.1%

Revenue 1Y (TTM)-99.97%

Revenue growth 3Y14.72%

Revenue growth 5Y-0.26%

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PULM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.

Based on estimates for the next years, PULM will show a very strong growth in Revenue. The Revenue will grow by 43.66% on average per year.

EPS Next Y-10%

EPS Next 2Y22.57%

EPS Next 3Y28.64%

EPS Next 5Y23.43%

Revenue Next Year1%

Revenue Next 2Y54.02%

Revenue Next 3Y58.32%

Revenue Next 5Y43.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PULM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PULM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PULM's earnings are expected to grow with 28.64% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.57%

EPS Next 3Y28.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PULM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PULMATRIX INC

NASDAQ:PULM (11/14/2025, 8:18:34 PM)

4.71

-0.18 (-3.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)10-16 2025-10-16

Earnings (Next)03-19 2026-03-19/bmo

Inst Owners9.34%

Inst Owner Change3.29%

Ins Owners0.66%

Ins Owner Change0%

Market Cap17.19M

Revenue(TTM)3.00K

Net Income(TTM)-6.22M

Analysts82.86

Price TargetN/A

Short Float %0.16%

Short Ratio0.41

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5730.5
P/FCF	N/A
P/OCF	N/A
P/B	3.63
P/tB	3.63
EV/EBITDA	N/A

EPS(TTM)-1.7

EYN/A

EPS(NY)-2.28

Fwd EYN/A

FCF(TTM)-1.64

FCFYN/A

OCF(TTM)-1.64

OCFYN/A

SpS0

BVpS1.3

TBVpS1.3

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-124.85%
ROE	-131.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-61.24%

ROA(5y)-54.83%

ROE(3y)-81.96%

ROE(5y)-75.71%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	19.97
Quick Ratio	19.97
Altman-Z	-46.25

F-Score3

WACC8.84%

ROIC/WACCN/A

Cap/Depr(3y)312.07%

Cap/Depr(5y)229.17%

Cap/Sales(3y)5.28%

Cap/Sales(5y)4.15%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)35.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.1%

EPS Next Y-10%

EPS Next 2Y22.57%

EPS Next 3Y28.64%

EPS Next 5Y23.43%

Revenue 1Y (TTM)-99.97%

Revenue growth 3Y14.72%

Revenue growth 5Y-0.26%

Sales Q2Q%-100%

Revenue Next Year1%

Revenue Next 2Y54.02%

Revenue Next 3Y58.32%

Revenue Next 5Y43.66%

EBIT growth 1Y16.24%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y69.13%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y68.52%

OCF growth 3YN/A

OCF growth 5YN/A

PULMATRIX INC / PULM FAQ

Can you provide the ChartMill fundamental rating for PULMATRIX INC?

ChartMill assigns a fundamental rating of 3 / 10 to PULM.

What is the valuation status of PULMATRIX INC (PULM) stock?

ChartMill assigns a valuation rating of 1 / 10 to PULMATRIX INC (PULM). This can be considered as Overvalued.

Can you provide the profitability details for PULMATRIX INC?

PULMATRIX INC (PULM) has a profitability rating of 0 / 10.

What is the earnings growth outlook for PULMATRIX INC?

The Earnings per Share (EPS) of PULMATRIX INC (PULM) is expected to decline by -10% in the next year.

PULMATRIX INC (PULM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PULMATRIX INC / PULM FAQ

Can you provide the ChartMill fundamental rating for PULMATRIX INC?

What is the valuation status of PULMATRIX INC (PULM) stock?

Can you provide the profitability details for PULMATRIX INC?

What is the earnings growth outlook for PULMATRIX INC?